These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 25956741

  • 1. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, Jones HM, Khurana P, Wallace C, Chapman T, Wear MA, Walkinshaw MD, Saxty B, Melton DW.
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [Abstract] [Full Text] [Related]

  • 2. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM.
    Oncotarget; 2016 Nov 15; 7(46):75104-75117. PubMed ID: 27650543
    [Abstract] [Full Text] [Related]

  • 3. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM.
    Nutrients; 2018 Nov 03; 10(11):. PubMed ID: 30400270
    [Abstract] [Full Text] [Related]

  • 4. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM.
    DNA Repair (Amst); 2010 Jul 01; 9(7):745-53. PubMed ID: 20418188
    [Abstract] [Full Text] [Related]

  • 5. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
    McNeil EM, Melton DW.
    Nucleic Acids Res; 2012 Nov 01; 40(20):9990-10004. PubMed ID: 22941649
    [Abstract] [Full Text] [Related]

  • 6. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
    Gentile F, Barakat KH, Tuszynski JA.
    Int J Mol Sci; 2018 Apr 30; 19(5):. PubMed ID: 29710850
    [Abstract] [Full Text] [Related]

  • 7. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
    Gentile F, Elmenoufy AH, Ciniero G, Jay D, Karimi-Busheri F, Barakat KH, Weinfeld M, West FG, Tuszynski JA.
    Chem Biol Drug Des; 2020 Apr 30; 95(4):460-471. PubMed ID: 31891209
    [Abstract] [Full Text] [Related]

  • 8. Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF.
    Chapman TM, Gillen KJ, Wallace C, Lee MT, Bakrania P, Khurana P, Coombs PJ, Stennett L, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B.
    Bioorg Med Chem Lett; 2015 Oct 01; 25(19):4097-103. PubMed ID: 26318993
    [Abstract] [Full Text] [Related]

  • 9. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L, Hayashi T, Rabeya RM, Nakajima S, Kanno Si, Takao M, Matsunaga T, Yoshino M, Ichikawa M, Riele Ht, Tsuchiya S, Tanaka K, Yasui A.
    DNA Repair (Amst); 2004 Feb 03; 3(2):135-43. PubMed ID: 14706347
    [Abstract] [Full Text] [Related]

  • 10. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
    Kirschner K, Melton DW.
    Anticancer Res; 2010 Sep 03; 30(9):3223-32. PubMed ID: 20944091
    [Abstract] [Full Text] [Related]

  • 11. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
    Li W, Melton DW.
    Oncogene; 2012 May 10; 31(19):2412-22. PubMed ID: 21996734
    [Abstract] [Full Text] [Related]

  • 12. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
    Usanova S, Piée-Staffa A, Sied U, Thomale J, Schneider A, Kaina B, Köberle B.
    Mol Cancer; 2010 Sep 16; 9():248. PubMed ID: 20846399
    [Abstract] [Full Text] [Related]

  • 13. Targeting DNA Repair in Tumor Cells via Inhibition of ERCC1-XPF.
    Elmenoufy AH, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, Weilbeer C, Mani RS, Barakat KH, Tuszynski JA, Weinfeld M, West FG.
    J Med Chem; 2019 Sep 12; 62(17):7684-7696. PubMed ID: 31369707
    [Abstract] [Full Text] [Related]

  • 14. XPF knockout via CRISPR/Cas9 reveals that ERCC1 is retained in the cytoplasm without its heterodimer partner XPF.
    Lehmann J, Seebode C, Smolorz S, Schubert S, Emmert S.
    Cell Mol Life Sci; 2017 Jun 12; 74(11):2081-2094. PubMed ID: 28130555
    [Abstract] [Full Text] [Related]

  • 15. Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation.
    Wang J, He H, Chen B, Jiang G, Cao L, Jiang H, Zhang G, Chen J, Huang J, Yang B, Zhou C, Liu T.
    Nat Commun; 2020 Feb 07; 11(1):786. PubMed ID: 32034146
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and in vitro cell-free/cell-based biological evaluations of novel ERCC1-XPF inhibitors targeting DNA repair pathway.
    Elmenoufy AH, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, Mani RS, Ciniero G, Tuszynski JA, Weinfeld M, West FG.
    Eur J Med Chem; 2020 Oct 15; 204():112658. PubMed ID: 32738410
    [Abstract] [Full Text] [Related]

  • 17. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.
    Tsodikov OV, Enzlin JH, Schärer OD, Ellenberger T.
    Proc Natl Acad Sci U S A; 2005 Aug 09; 102(32):11236-41. PubMed ID: 16076955
    [Abstract] [Full Text] [Related]

  • 18. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
    De Silva IU, McHugh PJ, Clingen PH, Hartley JA.
    Nucleic Acids Res; 2002 Sep 01; 30(17):3848-56. PubMed ID: 12202770
    [Abstract] [Full Text] [Related]

  • 19. Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
    Bergstralh DT, Sekelsky J.
    Trends Genet; 2008 Feb 01; 24(2):70-6. PubMed ID: 18192062
    [Abstract] [Full Text] [Related]

  • 20. Domain mapping of the DNA binding, endonuclease, and ERCC1 binding properties of the human DNA repair protein XPF.
    McCutchen-Maloney SL, Giannecchini CA, Hwang MH, Thelen MP.
    Biochemistry; 1999 Jul 20; 38(29):9417-25. PubMed ID: 10413517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.